SCHEMBL1007553

SCHEMBL1007553

CCc1nn(Cc2ccc(C(=O)N3CCCC3)cc2)c2c1CCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.48
CYP2D6 P10635 1/20 0.47
GRIA2 P42262 1/20 0.47
HPGD P15428 7/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
ADRB2 P07550 2/20 0.45
ALDH1A1 P00352 5/20 0.44
CHKA P35790 1/20 0.44
KCNK3 O14649 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41
MBTD1 Q05BQ5 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008169 0.90 HPGD (0.47) HRH3CYP2D6GRIA2HPGDMEN1
SCHEMBL1009726 0.86 HRH3 (0.50) HRH3CYP2D6GRIA2HPGDMEN1
SCHEMBL1007283 0.85 KDM4E (0.45) MEN1KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL1006577 0.85 GRIA2 (0.52) HRH3CYP2D6GRIA2HPGDMEN1
SCHEMBL1009877 0.83 HRH3 (0.51) HRH3CYP2D6GRIA2HPGDMEN1
SCHEMBL1007656 0.82 RAB9A (0.51) HPGDMEN1KMT2AALDH1A1CHKA
SCHEMBL1008235 0.81 HRH3 (0.46) HRH3CYP2D6GRIA2HPGDMEN1
SCHEMBL3134055 0.81 GRIA2 (0.69) CYP2D6GRIA2ALDH1A1MAPTHTT
SCHEMBL1007995 0.75 RARB (0.47) MEN1KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL300831 0.73 HPGD (0.68) HRH3HPGDMEN1KMT2AADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 HRH3 254/4885CYP2D6 3476/4885GRIA2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.